Category Archives: Cell Biology

Cell Biology

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in…

Study on combination with anti-PD1 therapy published by International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, the official journal of the American Society for Radiation Oncology (ASTRO)

Study on combinations with chemotherapy and anti-angiogenic therapy in human glioblastoma multiforme xenografts accepted for publication by Frontiers in Oncology, in its Radiation Oncology section

JERUSALEM, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (Nasdaq: DRTS and DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today the acceptance of two landmark pre-clinical studies in major peer-reviewed journals, both demonstrating the significant potential synergies between Alpha DaRT therapy and standard-of-care solid tumor therapies used today.

We are very excited to have these fantastic results recognized by two leading journals in our field, said Alpha Tau CEO Uzi Sofer. The potential synergy between Alpha DaRT and immunotherapies continues to be a strong area of focus for Alpha Tau, both in our ongoing pre-clinical work as well as in our endeavors to run multiple human clinical trials examining such combinations, including the trial currently underway combining Alpha DaRT with pembrolizumab in recurrent unresectable or metastatic head & neck squamous cell carcinoma patients. Similarly, the promising results for GBM patients are a key priority for Alpha Tau, as we continue to focus on advancing our solution for this deadly disease as quickly as possible. Armed with our Breakthrough Device Designation from the FDA in recurrent GBM, we have been progressing swiftly in large animal studies using our specially designed radial applicator for use in the brain, with the intent to begin a human clinical study in the near future.

Ronen Segal, CTO at Alpha Tau, added, These two significant studies continue to build on the ever-growing body of evidence that the Alpha DaRT may offer not only a compelling local radiation therapy solution, but also provide a broader systemic benefit through interaction with the immune system, and our incorporation of more advanced immunological analyses has improved our understanding of these amazing mechanisms. We also are impressed by the synergies we see with other mechanisms such as anti-angiogenesis and continue to explore those in parallel as well.

The first study, published in the International Journal of Radiation Oncology, Biology, Physics (known as the Red Journal) examines the transcriptional profile activated by Alpha DaRT, and its potential to enhance responsiveness to immune checkpoint inhibition of the programmed cell death protein 1 (PD-1) blockade. These results demonstrate potential synergies with immune stimulation in mice and support the further exploration of the Alpha DaRT as a compelling local radiation therapy with the potential to induce antitumor immunity.

In this pre-clinical study, Squamous Cell Carcinoma (SCC) tumor-bearing mice were treated with Alpha DaRT in combination with an anti-PD1 therapy (aPD-1). This group was compared to groups of mice treated with either Alpha DaRT or aPD-1 as a monotherapy, as well as to a control group. The efficacy of the treatment was evaluated over time, and the immune level of activation was analyzed through immunophenotyping and immunohistochemical staining sixteen days after Alpha DaRT source insertion.

The group treated with Alpha DaRT in combination with aPD-1 demonstrated delayed tumor development, higher T-effector cell infiltration with enhanced cytotoxic potential, and reduced systemic Myeloid-Derived Suppressor Cells (MDSCs) than either monotherapy alone. Gene expression and gene set enrichment analysis of mRNA levels seven days after Alpha DaRT insertion indicated that Alpha DaRT upregulated indicators of cell death, interferon signaling and myeloid related transcription, while downregulating indicators of DNA repair and cell proliferation. Moreover, immunophenotyping analysis at this timepoint showed that Alpha DaRT induced dendritic cell activation and affected the distribution of MDSC populations. Altogether, those findings demonstrated that the Alpha DaRT may offer tumor cell destruction via additional pathways beyond the immediate local impact of generating double-strand DNA breaks in tumor cells.

This studys authors conclude that Alpha DaRT can promote a hot tumor microenvironment and changes in immune suppression that lead to a potentiation of aPD-1 blockade-induced effector T-cell function and improved treatment efficacy. The authors observe that this study provides a rationale for investigating the combination of Alpha DaRT and aPD-1 clinically in SCC patients.

The full publication can be seen here: https://www.sciencedirect.com/science/article/pii/S0360301622031881

The second study, accepted for publication by Frontiers in Oncology in its Radiation Oncology section, examines the use of Alpha DaRT in treating human glioblastoma multiforme (GBM) xenografts, together with Temozolomide (TMZ), a standard-of-care chemotherapy, or Bevacizumab, a standard-of-care antiangiogenic therapy, both commonly used in treating GBM.

The results demonstrated that the combination of alpha radiation with TMZ doubled the cytotoxic effect of each of the treatments alone, and the surviving fraction of cancer cells treated by TMZ in combination with alpha irradiation was lower than alpha- or x-ray irradiation as monotherapies, or than by x-ray combined with TMZ. In addition, the treatment of GBM-bearing mice with Alpha DaRT and TMZ delayed tumor development more efficiently than the monotherapies. The studies further confirmed that, unlike other radiation types, alpha radiation did not increase the secretion of VEGF, a potent angiogenic factor that promotes tumor growth.

With respect to the combination of Alpha DaRT with anti-angiogenic therapy, Bevacizumab treatment introduced several days after Alpha DaRT implantation improved tumor control, compared to Bevacizumab or Alpha DaRT as monotherapies. The combination was also shown to be superior when starting Bevacizumab administration prior to Alpha DaRT implantation in large tumors relative to the size of the Alpha DaRT source. Bevacizumab induced a decrease in the endothelial cell marker CD31 staining in conjunction with the Alpha DaRT treatment, and increased the diffusive spread of Radium-224 daughter atoms in the tumor tissue, while decreasing their clearance from the tumor through the blood.

A summary abstract of the publication can be seen here:https://www.frontiersin.org/articles/10.3389/fonc.2022.888100/abstract

About Alpha DaRT

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including "anticipate," "being," "will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise capital when needed; (v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical studies to predict final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau's Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement lawsuits; (xii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; (xix) impacts from the COVID-19 pandemic; and the other important factors discussed under the caption "Risk Factors" in Alpha Tau's annual report filed on form 20-F with the SEC on March 28, 2022, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date subsequent to the date of this press release.

Investor Relations Contact

IR@alphatau.com

See the article here:
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in...

Cell Biology

Illumina Supports Enhanced Genomics-Enabled Discovery and Training Programs at UC San Diego – University of California San Diego

New laboratory automation technology will advance marine biomedical research, preparing students for biotech workforce

The Illumina Laboratory in Scholander Hall is one of two new automation Hubbs on the Scripps Oceanography campus. Photos by Erik Jepsen/University Communications.

Scripps Institution of Oceanography at the University of California San Diego announced today that Illumina, a global leader in development and application of genomic technology to improve human and environmental health, has provided researchers at the Center for Marine Biotechnology and Biomedicine at Scripps new scientific equipment to build genomics and laboratory automation-enabled discovery and training programs. Additionally, the Illumina Corporate Foundation donated $973,000 for additional materials to bring the equipment into operation and set up two laboratories on the Scripps Oceanography campus.

The Center for Marine Biotechnology and Biomedicine (CMBB) at Scripps focuses on research at the intersection of ocean sciences and human health. This support from Illumina will be used in the development of an automation hub to enable advanced synthetic biology, marine drug compound library curation, microbiome science, marine model organism cell biology and more. It will also become a training tool for students as they prepare to enter the biotechnology and genomics workforce.

Illumina is dedicated to creating opportunities to invite innovation and work collaboratively to unlock the potential of genomics, said Ashley Van Zeeland, vice president and head of Open Innovation at Illumina. With this equipment transfer, we hope to enable the acceleration of discoveries in marine biology that could improve both human and planetary health. We are also thrilled to get this automated technology into the hands of future scientists who will drive the next era of discovery at a scale we can hardly imagine today.

In the Illumina Lab in Scholander Hall, PhD student Kayla Wilson operates a new bulk reagent dispenser, which can rapidly fill well plates with two different liquids. Postdoctoral scholar Timothy Fallon programs a liquid handling robot.

This technology provided to Scripps Oceanography includes high-throughput screening equipment such as robotic liquid handlers, imaging processing stations, robotic arms for microplate handling, and more. The equipment will allow researchers to screen thousands of cells a day, observe protein evolutions, analyze DNA isolation for microbiome studies, characterize gene expression patterns during early development, determine the effects of toxicants on developing embryos, and more. High-capacity computing equipment and a new liquid-chromatography mass spectrometry system that enables rapid analysis was also included.

The two new laboratories will be operated by professors Bradley Moore and Amro Hamdoun. Moore is a marine chemical biologist and director of CMBB whose lab is focused on the discovery of drug leads and toxins from marine organisms and the development of biosynthetic cellular factories to make sustainable products. Hamdoun is a marine biologist working to generate new, genetically-enabled marine cell biological model organisms useful for ongoing biomedical research. Hamdoun Lab graduate students Yoon Lee, Evan Tjeerdema, and Nathan Chang are also examining how different environmental stressors and harmful chemicalssuch as persistent organic pollutants like flame retardants and legacy pesticidesinteract during early life stages of embryo development in sea urchins. These interactions have implications for understanding the health impacts of in utero chemical exposures for humans.

The use of genomics can aid the two Scripps labs in understanding chemical interactions between microorganisms and their chemical signals, thus enabling researchers to better understand human health and develop bio-based sustainable solutions.

A pipetting robot dilutes samples into a plate for imaging in the Illumina Laboratory in Hubbs Hall.

Much of this research requires individually analyzing hundreds of samples, a process that was pretty labor intensive and slow, said Hamdoun. This new equipment will allow researchers in his lab to image and process thousands of samples a week when they were previously limited to a couple hundred. The potential gains from this are substantial, and Hamdoun emphasizes that these tools will supercharge our work over the next few years. In particular, the new image processing station will allow the team to examine subcellular structures and expression patterns, allowing them to better understand how genes are patterned during embryonic development and how they change throughout this development.

Moore predicts that this equipment will allow for the discovery of even more new molecules with life-saving potential.

This support allows us to dream big, added Moore. It allows us to do experiments that we thought were going to be too difficult, too hard, or too expensive to do by allowing us to miniaturize the way we look at things, and be able to access so many more samples than we can do right now.

The equipment will also provide immense training opportunities for students, giving them experience in genomics and laboratory automation that is critical in todays life science and biotechnology workforce. The life science industry in San Diego is significant, supporting 175,000 jobs and generating about $41 billion in economic activity, according to Biocom, the California life sciences trade group.

We are thrilled to create opportunities that connect local university scientists to industry, said Sharon Vidal, senior director of corporate social responsibility at Illumina. Preparing our future workforce with access to the latest innovation in life science is a win win for all.

Moore Lab National Institutes of Health (NIH) Postdoctoral Fellow Timothy Fallon agrees.

From left to right, Hamdoun Lab graduate students Yoon Lee, Nathan Chang, and Evan Tjeerdema work in the new Illumina Laboratory in Hubbs Hall.

Todays students need to be familiar with solving biological problems at these huge scales, and that simply cant be done without the use of laboratory automation and big data experimental design and informatics, said Fallon, who helped spearhead the effort to develop the automation hub. This is why the support is so exciting. It allows us to build the facilities and coursework to both teach these cutting-edge topics, and to apply them in our research.

Hamdoun says that a significant portion of Scripps students end up pursuing careers in biotech, and these new systems will enable them to gain exposure to equipment that is commonplace in the industry much earlier in their education.

This allows students to come out of Scripps and UC San Diego better equipped to work and compete in the modern life sciences industry, says Hamdoun. This has always been very central to usto best prepare our students for positions in industry and increase the diversity of people working outside of academia.

For Moore Lab NIH Postdoctoral Fellow April Lukowski, the robotic liquid handlers are increasing her efficiency in X-ray crystallography, where she works to crystallize proteins to understand their structures. This process informs scientists how the proteins work so they can modify them into something that might be useful in drug development or manufacturing. She has gone from spending two hours manually pipetting 96 crystallization conditions to preparing the same amount of samples in only two minutes, dramatically speeding up the discovery process.

A new bulk reagent dispenser in the Illumina Lab in Scholander Hall can rapidly fill well plates with two different liquids. By increasing efficiency, this can speed up the discovery process.

While this equipment lives at UC San Diego, the automation hub at Scripps will benefit the broader research community, with access available for faculty and students from neighboring institutions such as San Diego State University.

With these significant contributions to Scripps, CMBB envisions the creation of a new facility that would become the Biomedical Automation Facility. This facility could become a state-of-the-art hub for high-throughput screening equipment and genomics-enabled discovery.

Illuminas support was a part of the Campaign for UC San Diego, a university-wide comprehensive fundraising effort that concluded June 30, 2022 and raised a total of $3.05 billion to continue the universitys nontraditional path toward revolutionary ideas, unexpected answers, lifesaving discoveries and planet-changing impact.

Link:
Illumina Supports Enhanced Genomics-Enabled Discovery and Training Programs at UC San Diego - University of California San Diego

Cell Biology

Stopping Moles from Turning into the Deadliest Type of Skin Cancer – Boston University

New research from BUs School of Medicine shows that activating particular set of genes helps prevent moles from mutating into melanoma

In a small patch of skin no bigger than an inch, there are millions of cells all performing various duties, like protecting us from bacteria and sensing temperature. A portion of them are melanocytes, a type of cell dedicated to producing melanin, the substance that gives our skin, eyes, and hair color. If triggered by UV light from the sun, melanocytes can form moles, or beauty marks.

Though harmless moles are extremely common, some keep growing and growing, and mutating, until they turn into melanoma, the most deadly type of skin cancer. While melanoma accounts for only about 1 percent of all skin cancers, it causes the majority of skin cancerrelated deaths, most commonly in people under the age of 30, especially women. Approximately 30 percent of melanomas begin in existing moles on the skin.

But why do some moles keep growing, while others dont? And can the same molecular function that stops regular moles from proliferating be applied to cancerous cells? A Boston Universityled team of researchers has some answersand their findings could lead to new drug targets for the successful treatment of cancer.

In a paper published in Nature Communications, they discovered that a signaling pathway that regulates growth in all cellscalled the Hippo tumor suppressor pathwayplays a significant role in preventing the transformation of moles into melanoma. The pathway regulates growth by modulating two proteins in the cell. When active, these proteins change gene expression within cells to growth state. When inactivated, which happens when an organ reaches its full size, for example, the gene expression will change to stop growth in cells.

The Hippo pathway can monitor how squished the cells are, which is basically how it knows that something is done growing, says Neil J. Ganem, a corresponding author on the paper and a BU School of Medicine associate professor of pharmacology and medicine who studies differences between cancer cells and normal cells.

We thought thats what could be happening in these moles, and that the Hippo pathway stops the continuing growth of a mole, Ganem adds. They looked at mice and human cells to see what happened when the Hippo pathway was turned on or off.

When activated, we show the Hippo pathway restrains the growth of melanocytes and helps prevent their transformation into melanoma, says Marc Vittoria (MED23), a fourth-year medical student at BU and lead author of the study. Similarly, we found that when the Hippo tumor suppressor pathway is suppressed in melanocytes, those cells rapidly go on to form melanoma in multiple experimental models.

The study was supported by a five-year grant from the Melanoma Research Alliance (MRA), called the Jackie King MRA Young Investigator Award, named after a 21-year-old who lost their life to melanoma. The MRA aims to bring young biologists with expertise in cancer cell biology into melanoma research.

Melanoma is one of these cancers that can affect young people, making it particularly devastating, Ganem says. If you find it early, its easy to treat, but when you catch it late, and [it becomes] invasive, that is most difficult to treat.

Doctors will often monitor moles that could be suspicious and opt to remove any that change over time. And discovering the mechanisms our cells employ to protect against tumor formation is key to identifying new drug targets for the successful treatment of cancer.

We hope our study highlights that targeted reactivation of the Hippo pathway is an attractive therapeutic possibility for the future treatment of melanoma, Ganem says. Though the research team focused on the role of the Hippo pathway in preventing moles from transforming into melanoma, they believe it may be acting similarly in other subtypes of cancer.

See the original post here:
Stopping Moles from Turning into the Deadliest Type of Skin Cancer - Boston University

Cell Biology

Will baldness soon be a thing of the past? – San Bernardino County Sun

Despair not, ye men and women with ever-thinning pates: The follicles on your bald, shiny scalps arent dead. Theyre just, sort of, sleeping.

Researchers at UC Irvine liken those follicles to a sea of 3D printers, just waiting for the command to power up. And theyve figured out how to issue that command, recently micro-injecting a protein that sounds a bit like Scooby Doo into mice.

Our results identify SCUBE3 as a hair-growth activator, says their paper, published recently in the journal Developmental Cell. When microinjected for 4 days recombinant human SCUBE3 induced significant hair growth in mouse back skin.

Not only did SCUBE3 wake up dormant follicles to grow mouse fur, it also worked to grow human hair that was grafted onto the mice. Given time, that human hair could grow (and grow, and grow) longer than the mouses own fur would grow; longer than the mouses body, longer than the mouses tail.

The results were very promising, said Yingzi Liu, one of the researchers.

If youre envisioning a mouse with a Farrah Fawcett do, youre not alone.More than 50 percent of women experience balding, according to the American Hair Loss Association, and by age 50 about 85 percent of men are balding as well.

There are but two medications that treat or stave off hair loss: finasteride (Propecia, Proscar) and minoxidil (Rogaine, Ioniten). It can take at least 6 months for either treatment to start showing results. Theres a long road ahead before SCUBE3 can be tested on people, but the researchers have applied for a patent and hope to get to clinical trials in the next five or so years.

Scientists really care not only that things work, but how they work, said Maksim Plikus, professor of developmental and cell biology and a study author. Right now, were focusing on a deep dive into the mechanisms. But we are excited to the level that we filed for a patent. And were thinking that it has potential for people.

The issue here is dysfunctional signaling, he said. Stem cells for hibernating follicles arent disappearing; theyre just extremely dormant because theyre not getting the message that they should perform.

Questions to be explored next include efficacy and safety. SCUBE3 is a naturally occurring molecule, Plikus said, but how much can be delivered without seeing side effects? How much is too much?

Plikus lab studies how complex tissues and organs regenerate under normal conditions and in response to injury or disease. It aims to understand the nature of stem cell regulatory networks and regenerative behavior in response to organ injury.

Our ongoing work shows that the regenerative abilities of adult mammalian skin are far greater than previously thought, the Plikus labs web site says. In the center of large skin wounds cells can acquire an embryonic-like state and develop new, fully functioning hair follicles. Collectively, regenerative events can be so efficient that several months after wounding, scar tissue can hardly be distinguished from the normal skin.

Further research will be conducted in the Plikus lab and at Amplifica Holdings Group Inc., a biotechnology company co-founded by Plikus.The study team included health professionals and academics from UCI, San Diego, China, Japan, Korea and Taiwan.

The work was supported by grants from the LEO Foundation, Chan Zuckerberg Initiative, W.M. Keck Foundation, National Science Foundation, National Institutes of Health, Simons Foundation, National Natural Science Foundation of China and Taiwans Ministry of Science and Technology.

And, in case youre wondering: Plikus and Liu have thick, healthy heads of hair!

Read more:
Will baldness soon be a thing of the past? - San Bernardino County Sun

Cell Biology

Renewal Bio Acquires Breakthrough Stem Cell Technology With Applications in Infertility and Longevity – Benzinga

Renewal Bio, a newly formed biotechnology company focused on infertility and longevity, today announced it has acquired an exclusive license from Yeda Research and Development Co Ltd, the commercial arm of the Weizmann Institute of Science, to a newly developed synthetic embryo technology. The technology was spearheaded by Prof. Jacob Hanna, Ph.D., M.D., as recently published in Cell, and builds on his research published in Nature last year. Renewal Bio plans to develop a bio platform that combines biology, hardware, and software to drive advancements and develop therapies for infertility, genetic diseases, lab-grown organs, and blood system rejuvenation.

The Problem: Humanity is Getting Older and Sicker

Since the turn of the century, developed nations have seen a clear trend: declining birth rates and fast aging populations. With significant socioeconomic implications, this trend threatens to upend health systems, retirement programs, and workforces across the globe. At the beginning of life, this is shown by a 5-10% increase in infertility treatments by U.S. couples each year. Towards the end of life, these issues are manifesting in fast-aging populations that balloon healthcare costs. In the U.S., the aging population is driving national health expenditures to increase at a rate of 5.5% per year, and are expected to reach more than $6 trillion annually by 2027.

The Solution: A Bio Platform to Renew Humanity

To solve these complex and compounding issues, Renewal Bio aims to make humanity younger and healthier by leveraging the power of the new stem cell technology. The technology can be applied to a wide variety of human ailments including infertility, genetic diseases, and longevity.

Renewal Bio's founding team includes:

Anyone interested in joining the company's mission of making humanity younger and healthier can learn more at renewal.bio.

About Renewal Bio

Founded in 2022, Renewal Bio mission is to renew humanity - making us younger and healthier. The company was founded by Omri Amirav Drory and Jacob Hanna to develop therapies ranging from infertility treatments to lab-grown organs using novel stem cell technology developed at the Weizmann Institute of Science. Learn more at renewal.bio.

About Yeda

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda currently manages approximately 500 unique patent families and has generated the highest income per researcher compared to any other academic technology transfer operation worldwide. Through the years, Yeda has contributed to the commercialization of a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and the CAR-T cancer therapy Yescarta. For more information, visit http://www.yedarnd.com/.

About the Weizmann Institute of Science

The Weizmann Institute of Science in Israel is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, Weizmann Institute's scientists are advancing research on the human brain, artificial intelligence, computer science and encryption, astrophysics and particle physics, and are tackling diseases such as cancer, while also addressing climate change through environmental, ocean, and plant sciences.

WebWireID292455

Go here to see the original:
Renewal Bio Acquires Breakthrough Stem Cell Technology With Applications in Infertility and Longevity - Benzinga

Cell Biology

Berkeley Lights and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of a Patient-Derived T cell…

EMERYVILLE, Calif., Aug. 4, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and the Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF), today announced the discovery, functional characterization, and recovery of a patient-derived T cell receptor sequence against a cancer neoantigen.

Together, Berkeley Lights and JLF were able to measure and identify T cells that were reactive against peptides used in a cancer vaccine that was administered to a patient to successfully stimulate an immune response against their advanced-stage pancreatic cancer leading to complete remission. The patient was treated under the supervision of physicians at Washington University in St. Louis.

The unprecedented speed of these results relied on the Berkeley Lights Beacon system. Applying the cell therapy development workflow, thousands of phenotypic measurements of single T cells were performed within one week. These measurements identified T cells that were cytotoxic and capable of secreting cytokines in response to antigen encounter, which were therefore predicted to be functional and subsequently sequenced at a single cell level. Cloning these T cell receptor sequences and expressing them in nave T cells enabled functional validation against an antigen of interest. This function-first measurement capability of the Berkeley Lights platform is a significant differentiator compared to frequency-based assessments of TCRs which result in functional validation bottlenecks, adding to a growing number of highly differentiated service offerings at Berkeley Lights.

"This unique workflow combines Berkeley Lights' core strength of functional analysis of live cells, along with the use of the new Biofoundry services organization to help customers accelerate their therapeutic discoveries in a faster, more scalable way," said Siddhartha Kadia, Ph.D., chief executive officer of Berkeley Lights. "We look forward to continuing to work with JLF and their partners in evaluating immune response to cancer vaccines, mapping TCRs to neoantigens and ultimately supporting this important work to save patient lives."

The JLF has the mission of providing personalized neoantigen cancer vaccines for appropriate patients who have advanced cancers and seek compassionate use treatment.

"The data is exceedingly clear that, together, we have successfully identified a functional, patient- and antigen-specific TCR validating both our treatment methodology and the Berkeley Lights technology for personalized cancer vaccines compared to conventional approaches," said William Hoos, president of the Jaime Leandro Foundation for Therapeutic Cancer Vaccines. "This is an exciting advancement in our mission."

From the clinical team, Dr. William Gillanders, professor of surgery at Washington University School of Medicine, commented:

"The Berkeley Lights technology can take immune monitoring to the next level by evaluating multiple quantitative measurements of live cell behavior and recover that cell for molecular characterization. This is going to be tremendously useful for the field by providing a much deeper dataset to further understand cancer vaccines and predict clinical outcomes as well as to serve the growing need of combination therapies where TCR-T can be utilized."

1Daniel A King, Amber R Smith, Gino Pineda, et al. Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and organoid profiling. medRxiv 2021.12.16.21267326; doi: https://doi.org/10.1101/2021.12.16.21267326

About Berkeley Lights

Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

Berkeley Lights' Beacon and Lightning systems and Culture Station instrument are FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.

SOURCE Berkeley Lights, Inc.

Link:
Berkeley Lights and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of a Patient-Derived T cell...

Cell Biology

Research Fellow, Mechanobiology Institute job with NATIONAL UNIVERSITY OF SINGAPORE | 303772 – Times Higher Education

Job Description

We are looking for a Postdoctoral Fellow with research experiences in Cell Biology or related Biomedical Sciences field. Relevant research areas include cell-cell junctions, cell signalling, cytoskeletal dynamics or related areas in mechanobiology. The successful candidate will lead a research project on the application of optogenetics to study adhesion proteins and cytoskeletons using advanced microscopy and molecular cell biology techniques.

Our laboratory is based at the Mechanobiology Institute (MBI), National University of Singapore (NUS). We are well equipped with state-of-the-art equipment and integrated core facilities support (microscopy, micro/nano-fabrication, protein expression and cloning, IT) as well as a vibrant and highly collaborative environment based on an Open Lab concept.

Compensation is internationally competitive and commensurate with experiences.

For more information, please visit our lab web site athttps://www.nanoscalemechanobiology.org

Qualifications

Candidates must have a Ph.D. degree in biology or related biomedical fields and outstanding publication record in relevant topics. Proficiency in mammalian cell biology, molecular biology, biochemistry, and live-cell fluorescence microscopy are desirable.

Covid-19 Message

At NUS, the health and safety of our staff and students are one of our utmost priorities, and COVID-vaccination supports our commitment to ensure the safety of our community and to make NUS as safe and welcoming as possible. Many of our roles require a significant amount of physical interactions with students/staff/public members. Even for job roles that may be performed remotely, there will be instances where on-campus presence is required.

Taking into consideration the health and well-being of our staff and students and to better protect everyone in the campus, applicants are strongly encouraged to have themselves fully COVID-19 vaccinated to secure successful employment with NUS.

More Information

Location: Kent Ridge CampusOrganization: Mechanobiology InstituteDepartment : ResearchEmployee Referral Eligible: NoJob requisition ID : 16760

Read the original:
Research Fellow, Mechanobiology Institute job with NATIONAL UNIVERSITY OF SINGAPORE | 303772 - Times Higher Education

Cell Biology

Maryland Today | Insight From an Inside-out Fruit – Maryland Today

As global temperatures rise and populations of bees and other pollinators dwindle, food crop production is increasingly becoming a puzzle for growers.

A new study by researchers at the University of Maryland puts some of the pieces together, providing insight into exactly how flowering plants develop fruits and seeds.

Understanding this process is especially important because common food cropssuch as peanuts, corn, rice and strawberriesare all fruits and seeds derived from flowers, said Zhongchi Liu, the studys senior author and a professor in the Department of Cell Biology and Molecular Genetics and affiliate professor in the Department of Plant Sciences and Landscape Architecture. Knowing how plants 'decide' to turn part of their flowers into fruit and seed is crucial to agriculture and our food supply.

Funded by the National Science Foundation, the study was publishedlast month in the journal Nature Communications. Liu and her team aimed to discover how fertilizationor pollinationtriggers a flowering plant to start the fruit development process. The team suspected that an internal communication system was responsible for signaling the plant to develop fruit, but the researchers were unsure how that system was being activated by fertilization or pollination.

To find out, the team simulated pollination and fruit development mechanisms using strawberry plants. Strawberries are particularly suited to fertilization modeling due to their unique structure and seed location.

As an inside-out fruit, strawberry seeds are much easier to manipulate and observe than the seeds of other fruits like tomatoes, Liu said. This made it easier for us to view the seeds and extract genetic information from them at multiple stages of plant development.

Liu and her team identified AGL62, a gene universally found in all flowering plants, as the trigger to a plants production of fruit and seed.

AGL62 stimulates the production of an essential plant growth hormone called auxin. Once the gene activates, auxin is synthesized to prompt the creation of seedcoat, the outer protective layer of a seed; the endosperm, the part of a seed that provides food for a developing plant embryo; and fruit. Auxins role in regulating endosperm growth is especially significant for researchers as it impacts the size of the grain and enlargement of the fruit.

Auxin levels can limit how big an endosperm can grow and how much nutrition endosperm can accumulate for a plant embryo, Liu said. More auxin can boost grain size and stimulate fruit enlargement. When theres less auxin, endosperms are unable to feed plant embryos properly and we end up with lowered crop productivitysmaller or deformed fruits that arent commercially viable.

Gerald Schoenknecht, a program director in NSFs Division of Integrative Organismal Systems, added, Strawberry fruits are textbook examples of how the plant hormone auxin produced in seeds controls fruit size. Discovering a gene that is required for auxin synthesis after fertilization may open avenues to achieve fruit development without fertilization.

See the rest here:
Maryland Today | Insight From an Inside-out Fruit - Maryland Today

Cell Biology

Glycan shield of the ebolavirus envelope glycoprotein GP | Communications Biology – Nature.com

Burk, R. et al. Neglected filoviruses. FEMS Microbiol. Rev. 40, 494519 (2016).

CAS PubMed PubMed Central Article Google Scholar

Jacob, S. T. et al. Ebola virus disease. Nat. Rev. Dis. Prim. 6, 131 (2020).

Article Google Scholar

Leroy, E. M. et al. Fruit bats as reservoirs of Ebola virus. Nature 438, 575576 (2005).

CAS PubMed Article Google Scholar

Mar Saz, A. et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol. Med. 7, 1723 (2015).

PubMed Article CAS Google Scholar

Goldstein, T. et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat. Microbiol. 3, 10841089 (2018).

CAS PubMed PubMed Central Article Google Scholar

Amman, B. R. et al. Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog. 8, e1002877 (2012).

Swanepoel, R. et al. Studies of reservoir hosts for Marburg virus. Emerg. Infect. Dis. 13, 1847 (2007).

CAS PubMed PubMed Central Article Google Scholar

Towner, J. S. et al. Marburg virus infection detected in a common African bat. PloS one 2, e764 (2007).

PubMed PubMed Central Article CAS Google Scholar

Team WER. Ebola virus disease in West Africathe first 9 months of the epidemic and forward projections. New England Journal of Medicine 371, 1481-1495 (2014).

Hoenen, T., Groseth, A. & Feldmann, H. Therapeutic strategies to target the Ebola virus life cycle. Nat. Rev. Microbiol. 17, 593606 (2019).

CAS PubMed Article Google Scholar

Lee, J. E. & Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol. 4, 621635 (2009).

CAS PubMed PubMed Central Article Google Scholar

Mehedi, M. et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J. Virol. 85, 54065414 (2011).

CAS PubMed PubMed Central Article Google Scholar

Volchkova, V. A., Feldmann, H., Klenk, H.-D. & Volchkov, V. E. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 250, 408414 (1998).

CAS PubMed Article Google Scholar

Aleksandrowicz, P. et al. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J. Infect. Dis. 204, S957S967 (2011).

CAS PubMed PubMed Central Article Google Scholar

Mulherkar, N., Raaben, M., de la Torre, J. C., Whelan, S. P. & Chandran, K. The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology 419, 7283 (2011).

CAS PubMed Article Google Scholar

Nanbo, A. et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 6, e1001121 (2010).

PubMed PubMed Central Article CAS Google Scholar

Saeed, M. F., Kolokoltsov, A. A., Albrecht, T. & Davey, R. A. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 6, e1001110 (2010).

PubMed PubMed Central Article CAS Google Scholar

Gong, X. et al. Structural insights into the Niemann-Pick C1 (NPC1)-mediated cholesterol transfer and Ebola infection. Cell 165, 14671478 (2016).

CAS PubMed PubMed Central Article Google Scholar

Miller, E. H. et al. Ebola virus entry requires the hostprogrammed recognition of an intracellular receptor. EMBO J. 31, 19471960 (2012).

CAS PubMed PubMed Central Article Google Scholar

Wang, H. et al. Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. Cell 164, 258268 (2016).

CAS PubMed PubMed Central Article Google Scholar

Saphire, E. O., Schendel, S. L., Gunn, B. M., Milligan, J. C. & Alter, G. Antibody-mediated protection against Ebola virus. Nat. Immunol. 19, 11691178 (2018).

CAS PubMed PubMed Central Article Google Scholar

Volchkov, V. E., Feldmann, H., Volchkova, V. A. & Klenk, H.-D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl Acad. Sci. 95, 57625767 (1998).

CAS PubMed PubMed Central Article Google Scholar

Sanchez, A. et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72, 64426447 (1998).

CAS PubMed PubMed Central Article Google Scholar

Ito, H., Watanabe, S., Sanchez, A., Whitt, M. A. & Kawaoka, Y. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J. Virol. 73, 89078912 (1999).

CAS PubMed PubMed Central Article Google Scholar

Malashkevich, V. N. et al. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9- resolution. Proc. Natl Acad. Sci. 96, 26622667 (1999).

CAS PubMed PubMed Central Article Google Scholar

Weissenhorn, W., Carf, A., Lee, K.-H., Skehel, J. J. & Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. cell 2, 605616 (1998).

CAS PubMed Article Google Scholar

Alvarez, C. P. et al. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76, 68416844 (2002).

CAS PubMed PubMed Central Article Google Scholar

Lin, G. et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 77, 13371346 (2003).

CAS PubMed PubMed Central Article Google Scholar

Simmons, G. et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305, 115123 (2003).

CAS PubMed Article Google Scholar

Collar, A. L. et al. Comparison of N-and O-linked glycosylation patterns of ebolavirus glycoproteins. Virology 502, 3947 (2017).

CAS PubMed Article Google Scholar

Dowling, W. et al. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J. Virol. 81, 18211837 (2007).

CAS PubMed Article Google Scholar

Iraqi, M. et al. N-Glycans mediate the ebola virus-GP1 shielding of ligands to immune receptors and immune evasion. Front. Cell. Infect. Microbiol. 10, 48 (2020).

CAS PubMed PubMed Central Article Google Scholar

Jeffers, S. A., Sanders, D. A. & Sanchez, A. Covalent modifications of the Ebola virus glycoprotein. J. Virol. 76, 1246312472 (2002).

CAS PubMed PubMed Central Article Google Scholar

Lennemann, N. J. et al. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. MBio 5, e0086200813 (2014).

PubMed PubMed Central Article CAS Google Scholar

Ritchie, G. et al. Identification of Nglycans from Ebola virus glycoproteins by matrixassisted laser desorption/ionisation timeofflight and negative ion electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom.: Int. J. Devoted Rapid Dissem. toMinute Res. Mass Spectrom. 24, 571585 (2010).

CAS Article Google Scholar

Wang, B. et al. Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function. J. Biol. Chem. 292, 58605870 (2017).

CAS PubMed PubMed Central Article Google Scholar

Lennemann, N. J., Walkner, M., Berkebile, A. R., Patel, N. & Maury, W. The role of conserved N-linked glycans on Ebola virus glycoprotein 2. J. Infect. Dis. 212, S204S209 (2015).

CAS PubMed PubMed Central Article Google Scholar

Furmanek, A. & Hofsteenge, J. Protein C-mannosylation: facts and questions. Acta Biochimica Polonica 47, 781789 (2000).

CAS PubMed Article Google Scholar

Julenius, K. NetCGlyc 1.0: prediction of mammalian C-mannosylation sites. Glycobiology 17, 868876 (2007).

CAS PubMed Article Google Scholar

Falzarano, D. et al. Ebola sGPthe first viral glycoprotein shown to be C-mannosylated. Virology 368, 8390 (2007).

CAS PubMed Article Google Scholar

Plewe, M. B. et al. Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors. ACS medicinal Chem. Lett. 11, 11601167 (2020).

CAS Article Google Scholar

Ren, J., Zhao, Y., Fry, E. E. & Stuart, D. I. Target identification and mode of action of four chemically divergent drugs against ebolavirus infection. J. medicinal Chem. 61, 724733 (2018).

CAS Article Google Scholar

Shaikh, F. et al. Structure-based in silico screening identifies a potent ebolavirus inhibitor from a traditional Chinese medicine library. J. medicinal Chem. 62, 29282937 (2019).

CAS Article Google Scholar

Zhao, Y. et al. Structures of Ebola virus glycoprotein complexes with tricyclic antidepressant and antipsychotic drugs. J. medicinal Chem. 61, 49384945 (2018).

CAS Article Google Scholar

Zhao, Y. et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535, 169172 (2016).

CAS PubMed PubMed Central Article Google Scholar

Cohen-Dvashi, H. et al. Structural basis for a convergent immune response against Ebola Virus. Cell host microbe 27, 418427.e414 (2020).

CAS PubMed Article Google Scholar

Dias, J. M. et al. A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18, 14241427 (2011).

CAS PubMed PubMed Central Article Google Scholar

Ehrhardt, S. A. et al. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nat. Med. 25, 15891600 (2019).

CAS PubMed Article Google Scholar

King, L. B. et al. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. Nat. Commun. 10, 18 (2019).

Article CAS Google Scholar

Milligan, J. C. et al. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell 185, 9951007 (2022).

Misasi, J. et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 13431346 (2016).

CAS PubMed PubMed Central Article Google Scholar

Murin, C. D. et al. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Rep. 35, 108984 (2021).

Originally posted here:
Glycan shield of the ebolavirus envelope glycoprotein GP | Communications Biology - Nature.com

Cell Biology

Associate Professor / Professor of Cancer Biology job with UNIVERSITY OF SOUTHAMPTON | 303905 – Times Higher Education

Cancer Sciences

Location: Southampton General HospitalSalary: 53,353 to 99,330Full Time PermanentClosing Date: Thursday 01 September 2022Interview Date: To be confirmedReference: 1928122CM

Associate Professor Salary: 53,353 67,060 per annum recruitment package will be commensurate with qualifications and experience (Level 6)

Professor Salary: Competitive from 70,119 per annum recruitment package will be commensurate with qualifications and experience (Level 7)

The University of Southampton seeks to recruit a new Associate Professor or Professor of Cancer Biology to expand our existing programmes and track record in this area, ideally in the field of lymphoid malignancy.

Over the last 30 years, our collaborative research teams, based on a single hospital site, have made important contributions to the study of normal and malignant lymphoid biology. Our research has helped transform the understanding and treatment of the most common adult leukaemia, Chronic Lymphocytic Leukaemia (CLL). Our discovery of two distinct CLL subsets has given clinicians and patients a much clearer indication of the likely disease course and has inspired the development of novel therapeutics. In parallel, our observations have driven major advances in lymphoma care, leading to the development and standardisation of effective new antibody treatments and optimal drug regimens (e.g. antibodies that target the CD20 protein). Through our leadership of international clinical trials, we have transformed the standard of care for different lymphoid malignancies (e.g. Hodgkin and Burkitt lymphoma) in the UK and internationally, affecting all stages of patient experience from diagnosis to treatment.

We now wish to further strengthen this area of our research with additional expertise in the fundamental biology of lymphoid malignancy. For the Professorial appointment, we seek an experienced and internationally recognised candidate with outstanding credentials in the field, someone with proven experience who will be attracted to a role in Southampton by our record in B cell biology and cancer immunology/immunotherapy, and our proven capabilities in clinical translation, taking results from the laboratory directly to patients. At the Associate Professor level, we would like to attract a rising star, with the potential, evidenced by early indicators, to become an international scientific leader of the future.

Successful candidates at both Associate Professor and Professor level will have a developing, or strong international profile in the molecular and cellular biology of cancer, respectively, and add synergy and/or a new dimension to our research activities. The successful individual will join a passionate team of basic and translational scientists working in close collaboration with clinical colleagues in our Biomedical Campus at Southampton General Hospital, in purpose-built laboratories in the Somers Building and the Centre for Cancer Immunology. Our work is under-pinned by multiple programme and accelerator awards from Cancer Research UK (CRUK), and houses a CRUK Centre, a CRUK/NIHR Experimental Cancer Medicine Centre, and a CRUK Clinical Trials Unit. Successful candidates at the Professorial level will also have senior research leadership experience and a more established track record of attracting substantive external research funding from research councils, charities and the commercial sector.

More than 250 researchers, clinicians and associated staff focus on all aspects of cancer research, with particular focus on cancer immunology/immunotherapy, cell biology and engineering antibodies to generate therapeutics. Through close interactions of our researchers with the clinical trials unit,we bring ideas and discoveries made in the laboratory into clinical practice as rapidly as possible and ensure that the mechanisms underlying cancer treatments are understood.

We welcome applications from all candidates with an interest in the role, and those who are committed to helping us create an inclusive work environment. We especially encourage applications from candidates from Black, Asian and Minority Ethnic communities, people who identify as LGBTQ+ and people with disabilities.

For further details about the post you are invited to contact the Head of School, Professor Jonathan Strefford jcs@soton.ac.uk

You should submit your completed online application form at https://jobs.soton.ac.uk. The application deadline will be midnight on the closing date stated above. Please submit details for 3 referees and include your CV and publication list with your application. If you need any assistance, please call Lauren Ward (Recruitment Team) on +44 (0) 23 8059 2750, or email recruitment@soton.ac.uk. Please quote reference 1928122CM on all correspondence.

View post:
Associate Professor / Professor of Cancer Biology job with UNIVERSITY OF SOUTHAMPTON | 303905 - Times Higher Education